// App-Quantinova.ai

POS1432 (2021) : SHORT-TERM RISK OF OSTEOPOROSIS IN ADULTS TREATED WITH CORTICOSTEROIDS: AN OBSERVATIONAL STUDY

Researchers

Presenter

  • E. Berni

Principal Investigators

  • S. Jenkins-Jones

  • M. Brown

  • C. Astbury

  • P. Hunt

  • C. Currie

Medical Centers

  • Pharmatelligence, Epidemiology, Cardiff, United Kingdom

  • AstraZeneca, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, Gothenburg, Sweden

  • AstraZeneca, BioPharmaceuticals Medical, CVRM Evidence, Gothenburg, Sweden

  • AstraZeneca, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Boston, United States of America

  • AstraZeneca, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden

  • Cardiff University School of Medicine, Cardiff, United Kingdom

Locations

  • United Kingdom

  • Sweden

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Endocrine/metabolic Diseases (ME)

Disease

  • Osteoporosis

  • Obesity

Biomarkers

  • Body mass index

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved